Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,010 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07354061RecruitingPhase 1/Phase 2
Ensartinib plus chemo before surgery for ALK+ lung cancer
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
Xi’an, ShanxiAges 18–75 - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT07241182Recruiting
Mushroom extract supplement for lung cancer chemo patients
This study tests whether a supplement from a medicinal mushroom (Antrodia cinnamomea, also known as niu zhang zhi) can improve quality of life for people with lung cancer who are receiving platinum-based chemotherapy.
TaipeiAges 18–99 - NCT07227480Recruiting
Lung cancer screening help via text message
This study uses text messages to help people get their yearly lung cancer screening. If you're between 50–80, have a significant smoking history, and haven't completed your annual screening yet, you may be able to join from home.
Rochester, New YorkAges 50–80 - NCT07168629Recruiting
Community health workers help you get lung cancer screening
This trial tests whether a community health worker can help you get a lung cancer screening. If you are at risk for lung cancer and go to certain community health centers, this program may help you get the screening you need.
Springfield, MassachusettsAges 50–80 - NCT07037758RecruitingPhase 1
Study of tarlatamab and AB248 for extensive stage small cell lung cancer
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–90 - NCT06950697Recruiting
Blood clot risk prediction for lung cancer patients on immunotherapy
This study builds a tool to predict blood clot risk in lung cancer patients receiving immune checkpoint inhibitors. Researchers will use your data to develop a more personalized risk assessment, which may help prevent dangerous clots during treatment.
Zhengzhou, HenanAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT06816121Recruiting
Blood test for early lung cancer in high-risk smokers
This study is evaluating a blood-based test that might detect lung cancer early, before symptoms appear. Researchers are looking for heavy smokers who have no signs of cancer, as well as those with suspicious lung nodules or confirmed lung cancer, to see if a simple blood draw could help identify cancer sooner.
Oklahoma City, OklahomaAges 30–80 - NCT06712355RecruitingPhase 3
Testing an experimental drug with chemo for newly diagnosed extensive-stage small cell lung cancer
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Tucson, ArizonaAges 18 years+ - NCT06646276RecruitingPhase 3
New drug combo vs standard care for first-line extensive-stage small cell lung cancer
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
Daphne, AlabamaAges 18 years+ - NCT06598306RecruitingPhase 1
Tarlatamab injection for advanced small cell lung cancer
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06437509RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06217757RecruitingPhase 1/Phase 2
LDRT, immunotherapy, chemo, and olaparib for SLFN-11 positive SCLC
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
Chengdu, SichuanAges 18–75 - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Santa Barbara, CaliforniaAges 18–100 - NCT05701176Recruiting
Imaging scan to see how anti–PD-1 changes lung cancer cells
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
AmsterdamAges 18 years+ - NCT05445791RecruitingPhase 3
Metformin plus targeted lung cancer drugs for EGFR-mutated cancer
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Mexico CityAges 18 years+ - NCT03848052Recruiting
Study of lung cancer care in France since 2015
This trial tracks how lung cancer is treated in France, looking at what therapies were used and how care has evolved since 2015. It may help doctors improve future treatment choices by understanding real-world care patterns.
AngersAges 18 years+ - NCT02421718Recruiting
Follow-up program for lung cancer and related conditions after radiation
This trial studies a standard follow-up plan to help you stay on track after radiation treatment for lung cancers or certain related conditions. It may help your care team monitor symptoms and outcomes in a consistent way.
Groningen, Provincie GroningenAges 18 years+ - NCT04375904RecruitingPhase 2
Stereotactic radiation for central lung tumors
This trial tests a precise, high-dose radiation treatment aimed at central lung tumors. It may help people who cannot have lung surgery and whose tumors can be safely targeted near sensitive organs.
DublinAges 18 years+ - NCT04485286RecruitingPhase 2
PET scan tracer to find lung or pancreas radiation injury
This Phase 2 study tests a special PET scan tracer to help doctors spot tissue damage after radiation treatment in people with certain lung or pancreatic cancers. The goal is to improve detection and planning around chemoradiation and surgery.
Boston, MassachusettsAges 18–80 - NCT07661966Recruiting
Bright light therapy for melanoma or lung cancer patients starting immunotherapy
This study tests if daily bright light therapy can help people with advanced melanoma or lung cancer feel better during their first immunotherapy treatment. The light box is used at home for a short time each morning.
New York, New YorkAges 18 years+ - NCT07367581Recruiting
Comparing two nerve blocks for lung surgery pain
This study compares two types of numbing blocks to manage pain after lung cancer surgery. If you qualify, you'll receive one of these blocks to see which provides better pain relief.
CairoAges 18–65 - NCT04691817RecruitingPhase 1/Phase 2
Testing tocilizumab plus atezolizumab after lung cancer treatment failure
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,010 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.